Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
18
CMMB Quote, Financials, Valuation and Earnings
Last price:
$1.66
Seasonality move
:
25.93%
Day range:
$1.71 - $1.98
52-week range:
$1.71 - $9.84
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.99x
Volume:
146.4K
Avg. volume:
100K
1-year change:
-77.39%
Market cap:
$11.1M
Revenue:
--
EPS (TTM):
-$1.86
Analysts' Opinion
-
Consensus RatingChemomab Therapeutics Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $17.50, Chemomab Therapeutics Ltd. has an estimated upside of 872.22% from its current price of $1.80.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $10.00 representing 100% downside risk from its current price of $1.80.
Fair Value
-
According to the consensus of 1 analyst, Chemomab Therapeutics Ltd. has 872.22% upside to fair value with a price target of $17.50 per share.
CMMB vs. S&P 500
-
Over the past 5 trading days, Chemomab Therapeutics Ltd. has underperformed the S&P 500 by -7.54% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Chemomab Therapeutics Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Chemomab Therapeutics Ltd. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Chemomab Therapeutics Ltd. reported revenues of --.
Earnings Growth
-
Chemomab Therapeutics Ltd. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Chemomab Therapeutics Ltd. reported earnings per share of -$0.28.
Enterprise value:
874.2K
EV / Invested capital:
0.08x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-0.04x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-68.37%
Net Income Margin (TTM):
--
Return On Equity:
-82.89%
Return On Invested Capital:
-81.61%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$64.6K | -$43.1K | -- | -- | -- | |
| Operating Income | -$30M | -$15.5M | -$10.9M | -$3.7M | -$1.9M | |
| EBITDA | -$30M | -$15.4M | -- | -$3.7M | -- | |
| Diluted EPS | -$2.55 | -$0.99 | -$1.86 | -$0.20 | -$0.28 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $65.8M | $48.7M | $22.4M | $19.9M | $11.9M | |
| Total Assets | $67.4M | $50.2M | $23.4M | $20.9M | $12.4M | |
| Current Liabilities | $1.6M | $5.5M | $5.4M | $4.3M | $1.1M | |
| Total Liabilities | $1.9M | $5.6M | $5.4M | $4.6M | $1.1M | |
| Total Equity | $65.5M | $44.6M | $18M | $16.3M | $11.2M | |
| Total Debt | $298K | $118K | $5K | $230K | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2022-12-31 | 2023-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$12.4M | -$20.3M | -$23.6M | -$5.8M | -$3.9M | |
| Cash From Investing | -$45.2M | $19.5M | $15.8M | $9.4M | $1.9M | |
| Cash From Financing | $61.1M | -$804.8K | $3.5M | -$850.3K | $2.1M | |
| Free Cash Flow | -$12.6M | -$20.4M | -$23.6M | -$5.8M | -$3.9M | |
CMMB
Sector
Market Cap
$11.1M
$28.2M
Price % of 52-Week High
18.29%
50.25%
Dividend Yield
0%
0%
Shareholder Yield
0.45%
-1.54%
1-Year Price Total Return
-77.39%
-18.1%
Beta (5-Year)
0.504
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.95
200-day SMA
Sell
Level
$3.89
Bollinger Bands (100)
Sell
Level
2.4 - 3.42
Chaikin Money Flow
Sell
Level
-20.9M
20-day SMA
Sell
Level
$2.29
Relative Strength Index (RSI14)
Sell
Level
27.63
ADX Line
Sell
Level
33.71
Williams %R
Buy
Level
-91.5094
50-day SMA
Sell
Level
$2.63
MACD (12, 26)
Sell
Level
-0.22
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Neutral
Level
20.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.4674)
Sell
CA Score
(Annual)
Level (-2.591)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (8.988)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Chemomab Therapeutics Ltd. is a clinical-stage biotech company, which engages in the provision of therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The company was founded by Adi Mor on September 22, 2011 and is headquartered in Tel Aviv, Israel.
Stock Forecast FAQ
In the current month, CMMB has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CMMB average analyst price target in the past 3 months is $17.50.
-
Where Will Chemomab Therapeutics Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Chemomab Therapeutics Ltd. share price will rise to $17.50 per share over the next 12 months.
-
What Do Analysts Say About Chemomab Therapeutics Ltd.?
Analysts are divided on their view about Chemomab Therapeutics Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Chemomab Therapeutics Ltd. is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is Chemomab Therapeutics Ltd.'s Price Target?
The price target for Chemomab Therapeutics Ltd. over the next 1-year time period is forecast to be $17.50 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CMMB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Chemomab Therapeutics Ltd. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of CMMB?
You can purchase shares of Chemomab Therapeutics Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Chemomab Therapeutics Ltd. shares.
-
What Is The Chemomab Therapeutics Ltd. Share Price Today?
Chemomab Therapeutics Ltd. was last trading at $1.66 per share. This represents the most recent stock quote for Chemomab Therapeutics Ltd.. Yesterday, Chemomab Therapeutics Ltd. closed at $1.80 per share.
-
How To Buy Chemomab Therapeutics Ltd. Stock Online?
In order to purchase Chemomab Therapeutics Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get CMMB Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CMMB
Sector
P/E ratio
--
23.92x
PEG ratio
-0.01x
-0.01x
P/B ratio
0.99x
1.83x
Price / LTM sales
--
1.61x
Growth Metrics
CMMB
Sector
Revenue growth
--
4.6%
Earnings growth
-42.02%
10.88%
Revenue (5-year growth)
--
6.46%
Earnings forecast
-$0.04
-$0.21
Profitability
CMMB
Sector
Profitability FY 2024
-$53.3K
$3.5M
Return on invested capital
-81.61%
-31.84%
Return on assets
-68.37%
-27.96%
Return on equity
-82.89%
-37.63%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Dec
29
Estimated Next Earnings Date
Mar
30
Balance Sheet
CMMB
Sector
Total cash
$10.2M
$26.3M
Short term investments
$8.2M
$25.7M
Total assets
$17M
$76.9M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 29
Galecto, Inc. [GLTO] is down 12.13% over the past day.
Sell
20
SMX alert for Dec 29
SMX (Security Matters) Plc [SMX] is down 27.67% over the past day.
Sell
11
CDNAF alert for Dec 29
Canadian Tire Corp. Ltd. [CDNAF] is up 11.94% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
